Phentermine (generic), Ionamin, Adipex-P Newswire

Phentermine (generic), Ionamin, Adipex-P Newswire

Comprehensive Real-Time News Feed for Phentermine (generic), Ionamin, Adipex-P.

Results 1 - 20 of 111 in Phentermine (generic), Ionamin, Adipex-P

  1. Eisai Inc. Announces Lorcaserin HCl CAMELLIA-TIMI 61 Study Will...Read the original story

    Tuesday | BioSpace

    Eisai Inc. Announces Lorcaserin HCl CAMELLIA-TIMI 61 Study Will Continue As Planned Based On Interim Safety Analysis By Independent Data Monitoring Committee /PRNewswire/ -- Eisai Inc. today announced that the ongoing investigational CAMELLIA-TIMI 61 study of lorcaserin will continue as planned, based on the recommendation of an independent Data Monitoring Committee after it completed a pre-specified interim safety analysis evaluating the incidence of MACE events, defined as cardiovascular death, myocardial infarction or stroke. The DMC will continue to monitor the ongoing safety of lorcaserin as planned.

    Comment?

  2. Zacks: Brokerages Expect VIVUS, Inc. (VVUS) Will Post Earnings of -$0.13 Per ShareRead the original story w/Photo

    Wednesday Jun 7 | AmericanBankingNews.com

    Wall Street analysts predict that VIVUS, Inc. will announce earnings per share of for the current fiscal quarter, according to Zacks Investment Research . Zero analysts have provided estimates for VIVUS's earnings.

    Comment?

  3. Anti-obesity activity, acute toxicity, and chemical constituents of...Read the original story w/Photo

    Monday Jun 5 | BioMed Central

    Viola mandshurica has traditionally been used as an expectorant, diuretic, and anti-inflammatory drug. The present study was designed to test the hypothesis that low doses of two different V. mandshurica extracts have anti-obesity effects.

    Comment?

  4. Obesity Management Market Will Increase at a CAGR of 4.9% During 2017-2027 by Future Market InsightsRead the original story w/Photo

    Friday Jun 2 | SBWire

    High costs involved in the research & development of obesity drugs, coupled with limited financial support, are collectively a great challenge for adoption of obesity management solutions. Additionally, long gestation time needed for R&D activities, and the inclusion of clinical trials required to test these drugs hikes the expenditure significantly.

    Comment?

  5. Analysts Expect VIVUS, Inc. (VVUS) Will Announce Earnings of -$0.13 Per ShareRead the original story w/Photo

    Monday May 22 | IntersportsWire

    Equities analysts forecast that VIVUS, Inc. will report earnings per share of for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for VIVUS's earnings.

    Comment?

  6. Taking diet pills may harm hormones, mental health of teens: StudyRead the original story

    May 20, 2017 | Newkerala.com

    Washington D.C. [U.S.A.], May 20 : Do not let your teenage daughter or son turn to diet pills to lose weight as a study has found that these supplements contain toxic chemicals that can affect their hormones, growth and mental health. According to researchers, diet pills are unsafe for all ages, especially for teenagers, because the pills interfere with their systems and result in nutritional deficiencies, particularly of iron and calcium.

    Comment?

  7. Two charged with drug traffickingRead the original story

    May 18, 2017 | News Tribune

    James Freant, 36, of Wentzville, and Sheila Kean, 51, of Wright City, are also charged with two counts each of possession of a controlled substance. Officers were called to the 1700 block of Jefferson Street on May 5 after three people appeared to be tampering with a motor vehicle, according to Jefferson City Police Department probable cause statements.

    Comment?

  8. VIVUS (VVUS) Earns News Sentiment Score of 0.16Read the original story w/Photo

    May 15, 2017 | The Breeze

    News coverage about VIVUS has trended somewhat positive on Monday, Alpha One Sentiment reports. The research group, a division of Accern, identifies negative and positive press coverage by analyzing more than twenty million news and blog sources.

    Comment?

  9. VIVUS, Inc. (VVUS) Posts Quarterly Earnings Results, Beats Expectations By $0.12 EPSRead the original story w/Photo

    May 14, 2017 | IntersportsWire

    VIVUS, Inc. issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported earnings per share for the quarter, beating the Zacks' consensus estimate of by $0.12.

    Comment?

  10. Herbal Supplement Market Pegged for Robust Expansion by 2021Read the original story w/Photo

    May 12, 2017 | SBWire

    Geographically herbal supplement market is segmented into North America, Latin America, Eastern Europe, Western Europe, Asia Pacific excluding Japan, Japan and Middle East & Africa. Western Europe and Eastern Europe together holds the highest market share in terms of revenue, however Asia Pacific market is growing at a highest rate among all other segments; China and India are two large contributor behind the growth rate of Asia Pacific.

    Comment?

  11. Obesity Management Market to Worth US$ 1,078.9 by 2027 EndRead the original story

    May 12, 2017 | PR.com

    High costs involved in the research & development of obesity drugs, coupled with limited financial support, are collectively a great challenge for adoption of obesity management solutions. Additionally, long gestation time needed for R&D activities, and the inclusion of clinical trials required to test these drugs hikes the expenditure significantly.

    Comment?

  12. New weight loss drugsRead the original story w/Photo

    May 11, 2017 | HEALTH'Sass

    As we slog into the 21st century, fat shamed, doctor shamed, spouse shamed, self shamed, what about a magic pill? I was clapped onto amphetamines when I was 12--lost enormous amounts of weight three times, but it always found me again. Now, according to an article in ELLE by Joseph Hooper, the FDA has approved four new drugs to combat obesity: Qsymia and Belviq , Contrave and Saxenda .

    Comment?

  13. Zacks: Analysts Anticipate VIVUS, Inc. (VVUS) Will Post Earnings of -$0.13 Per ShareRead the original story w/Photo

    May 11, 2017 | AmericanBankingNews.com

    Wall Street analysts predict that VIVUS, Inc. will report earnings per share of for the current quarter, according to Zacks Investment Research . Zero analysts have provided estimates for VIVUS's earnings.

    Comment?

  14. Favorable Media Coverage Very Likely to Affect VIVUS (VVUS) Share PriceRead the original story w/Photo

    May 9, 2017 | Daily Political

    News headlines about VIVUS have been trending positive on Tuesday, AlphaOne Sentiment reports. The research firm, a service of Accern, ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time.

    Comment?

  15. Global Anti-Obesity Drugs Market to Observe Strong Development by 2022Read the original story w/Photo

    May 9, 2017 | SBWire

    According to World Health Organization , obesity refers a disorder of accumulation of excessive fat that can impair health. Body Mass Index is an index of weight for height, which is a measure for classifying obesity and overweight.

    Comment?

  16. Analysts Expect VIVUS, Inc. (VVUS) Will Announce Earnings of -$0.13 Per ShareRead the original story w/Photo

    May 7, 2017 | IntersportsWire

    Equities analysts forecast that VIVUS, Inc. will report earnings per share of for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for VIVUS's earnings.

    Comment?

  17. VIVUS, Inc. (VVUS) Posts Earnings Results, Beats Estimates By $0.12 EPSRead the original story w/Photo

    May 4, 2017 | Daily Political

    VIVUS, Inc. announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported earnings per share for the quarter, topping the consensus estimate of by $0.12.

    Comment?

  18. Cardiometabolic disease staging score quantifies diabetes riskRead the original story w/Photo

    May 4, 2017 | PhysOrg Weblog

    For overweight and obese individuals, the Cardiometabolic Disease Staging score can quantify the risk of diabetes and predict the effectiveness of weight-loss therapy for preventing diabetes, according to research published online April 28 in Diabetes Care . Fangjian Guo, M.D., Ph.D., from the University of Texas Medical Branch in Galveston, and W. Timothy Garvey, M.D., from the University of Alabama at Birmingham, pooled data from 3,040 overweight and obese participants in three randomized trials examining the efficacy and safety of phentermine/topiramate extended release for weight loss.

    Comment?

  19. VIVUS (VVUS) Earns News Sentiment Score of -0.08Read the original story w/Photo

    May 2, 2017 | IntersportsWire

    Media coverage about VIVUS has been trending somewhat negative on Tuesday, according to AlphaOne. The research firm, a service of Accern, ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time.

    Comment?

  20. VIVUS, Inc. (VVUS) Shares Bought by Renaissance Technologies LLCRead the original story w/Photo

    May 2, 2017 | IntersportsWire

    Renaissance Technologies LLC raised its stake in shares of VIVUS, Inc. by 18.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,377,354 shares of the biopharmaceutical company's stock after buying an additional 695,512 shares during the period.

    Comment?